Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) — Strategic Asset Allocation Index
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) has a Strategic Asset Allocation Index of 26.7% as of June 2023. Strategic assets (PP&E of CN¥574.79 Million plus long-term investments of CN¥-) total CN¥574.79 Million, measured against net assets of CN¥2.15 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See how leveraged is Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's balance sheet to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Strategic Asset Allocation Index (2010–2022)
This chart shows how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Strategic Asset Allocation Index has evolved across 13 annual periods from 2010 to 2022. As of June 2023, the index stands at 26.7%, representing strategic assets of CN¥574.79 Million against net assets of CN¥2.15 Billion CNY. For live market cap and overall valuation, see 300357 market cap overview.
Annual Strategic Asset Allocation Index for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2010–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2010 to 2022, covering 13 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See 300357 net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 21.9% | CN¥444.61 Million | CN¥444.61 Million | CN¥- | CN¥2.03 Billion | ▲ +5.1 pp |
| 2021 | 16.8% | CN¥301.62 Million | CN¥301.62 Million | CN¥- | CN¥1.80 Billion | ▲ +1.1 pp |
| 2020 | 15.7% | CN¥240.16 Million | CN¥240.16 Million | CN¥- | CN¥1.53 Billion | ▲ +1.1 pp |
| 2019 | 14.6% | CN¥197.63 Million | CN¥197.63 Million | CN¥- | CN¥1.35 Billion | ▼ -0.5 pp |
| 2018 | 15.1% | CN¥150.68 Million | CN¥137.68 Million | CN¥13.00 Million | CN¥995.42 Million | ▼ -1.9 pp |
| 2017 | 17.0% | CN¥136.56 Million | CN¥123.56 Million | CN¥13.00 Million | CN¥801.26 Million | ▼ -1.0 pp |
| 2016 | 18.1% | CN¥118.53 Million | CN¥118.53 Million | CN¥- | CN¥655.58 Million | ▲ +1.4 pp |
| 2015 | 16.6% | CN¥96.97 Million | CN¥96.97 Million | CN¥- | CN¥582.91 Million | ▲ +4.9 pp |
| 2014 | 11.7% | CN¥60.28 Million | CN¥60.28 Million | CN¥- | CN¥513.55 Million | ▼ -9.4 pp |
| 2013 | 21.1% | CN¥53.18 Million | CN¥53.18 Million | CN¥- | CN¥251.92 Million | ▼ -2.9 pp |
| 2012 | 24.0% | CN¥43.60 Million | CN¥43.60 Million | CN¥- | CN¥181.38 Million | ▼ -8.6 pp |
| 2011 | 32.6% | CN¥41.60 Million | CN¥41.60 Million | CN¥- | CN¥127.61 Million | ▼ -15.7 pp |
| 2010 | 48.3% | CN¥43.73 Million | CN¥43.73 Million | CN¥- | CN¥90.44 Million | — |